This is a contrast between CRISPR Therapeutics AG (NASDAQ:CRSP) and OncoCyte Corporation (NYSEAMERICAN:OCX) based on their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||58||0.00||34.37M||-0.46||0.00|
Table 1 demonstrates CRISPR Therapeutics AG and OncoCyte Corporation’s gross revenue, earnings per share (EPS) and valuation.
Table 2 shows us CRISPR Therapeutics AG and OncoCyte Corporation’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||59,279,061.75%||-2.6%||-2%|
8.3 and 8.3 are the respective Current Ratio and a Quick Ratio of CRISPR Therapeutics AG. Its rival OncoCyte Corporation’s Current and Quick Ratios are 6.7 and 6.7 respectively. CRISPR Therapeutics AG has a better chance of clearing its pay short and long-term debts than OncoCyte Corporation.
CRISPR Therapeutics AG and OncoCyte Corporation Recommendations and Ratings are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
CRISPR Therapeutics AG’s upside potential is 9.04% at a $72 consensus target price.
Institutional and Insider Ownership
CRISPR Therapeutics AG and OncoCyte Corporation has shares owned by institutional investors as follows: 46.8% and 33.5%. About 0.4% of CRISPR Therapeutics AG’s share are owned by insiders. Competitively, insiders own roughly 15% of OncoCyte Corporation’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
For the past year CRISPR Therapeutics AG’s stock price has bigger growth than OncoCyte Corporation.
CRISPR Therapeutics AG beats on 7 of the 10 factors OncoCyte Corporation.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.